As of 2026-10-16, 5 AI models estimate ORNBV median target 106.18 € (+22.9% vs spot 86.40 €, model agreement 0.67). Analyst consensus 77.33 € (6 analysts). Experimental comparison — not investment advice.
AI Consensus
Model estimate
106.18 €
Pure model estimate — no analyst blending
Gap
+22.9%
Agreement
0.675/5 models
Raw 0.67
Dispersion
σ 16.3%
Analyst consensus
77.33 €(6 analysts)
Calibrated blend (research)
97.53 €
AI Summary
5 of 5 AI models are positive on ORNBV.
Estimate History AI model estimates and spot price over time
Loading...
What Changed Today
Consensus Est.:106.18→106.18(+0.0%)
no-changeassumptions-stablethesis-intact
What Changed (7 days)
Between 2026-10-09 and 2026-10-16, the 5-model AI consensus estimate for ORNBV moved from 118.68 € to 106.18 € (-10.5%); median WACC 8.0% → 8.0% (+0.00 pp); median terminal growth 2.0% → 2.0% (+0.00 pp); model dispersion σ 14.9% → 16.3%. Experimental model estimates — not investment advice.
Based on spot price 86.40 € and raw DCF model (before caps and calibration).
Fundamentals
EBIT Margin30.6%
EBITDA Margin38.6%
ROE45.7%
Net Debt / EBITDA0.0x
P/E Trailing20.7x
EV / EBITDA15.3x
P/B9.6x
Analyst Range55.00 – 88.00
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing
Subscribe to Email UpdatesFree · No spam · Unsubscribe anytime · Privacy Policy
AI Investor Barometer · 2026-10-16
All content is generated by AI models and may contain errors. This is an experimental tool — not investment advice, research, or recommendation. About · Methodology · Terms of Use · Privacy Policy
Key driver: Rapid commercial growth and high-margin royalty expansion from Nubeqa (darolu...
AI consensus estimate 106.18 22.9% above the current price.
Model agreement is moderate (0.67).
Analyst consensus: 77.33 (AI +37.3%).
Bear Case (min)
93.38 €
8.1%
Base Case (median)
106.18 €
+22.9%
Bull Case (max)
140.27 €
62.3%
Bear/Base/Bull: pure model range (12-month values)